

March 17th, 2025

BESREMi® (ropeginterferon alfa-2b-njft) injection, 500 mcg/mL solution in a single-dose prefilled syringe, for subcutaneous use (preservative free)

US-Authorized Product - Now Available

Dear Doctor/Nurse/Pharmacist,

Due to a critical shortage of PEGASYS (peginterferon alfa-2a) injection in Canada, and given the medical importance of interferon-based therapy, Health Canada has permitted the exceptional, temporary importation and sale of **US-authorized BESREMi (ropeginterferon alfa-2b-njft)** injection with English-only labels by FORUS Therapeutics Inc.

Healthcare professionals should be aware that BESREMi and PEGASYS are distinct and different medicinal products with different active pharmaceutical ingredients. The Risk Communication Letter can be viewed by clicking the following links in [English](#) and [French](#).

The Risk Communication Letter, US-authorized BESREMi Prescribing Information, Instructions for Use, Medication Guide, and other pertinent information, is available electronically by scanning the QR code, or visiting www.BESREMiEI.com.




US-authorized BESREMi will be available to order as of: March 17th, 2025

Product Code	Description	Pack Size	Availability Date
BC, AB, SK: 1526 6500-01 All other provinces: DR001845	BESREMi (ropeginterferon alfa-2b-njft) injection, 500 mcg/mL solution in a single-dose prefilled syringe, for subcutaneous use (preservative free)	1	March 17 th , 2025

For **BC, AB, SK**: To order product once it is available, please send an email to FORUS-CSR@innomar-strategies.com or call 1-866-542-7500.

For **all other provinces**: To order product once it is available, please send an email to : specialtylogistics@innomar-strategies.com, call 866-949-9927, fax 866-949-9917, or order online at : <https://innomar.specialtyorder.com/user/login>).

If you have questions regarding ordering BESREMi, please use the above contact information as appropriate for your province. If you have any other questions regarding BESREMi, please contact FORUS Medical Information (email: medinfo@forustherapeutics.com; call: 1-866-542-7500).

Sincerely,

 Kevin Leshuk
 President and CEO

BESREMi® is a registered trademark of PharmaEssentia Corporation used under license by FORUS Therapeutics Inc. All rights reserved.